Pliant Therapeutics
Logotype for Pliant Therapeutics Inc

Pliant Therapeutics (PLRX) investor relations material

Pliant Therapeutics Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Pliant Therapeutics Inc
Q3 2026 earnings summary12 Nov, 2026

Executive summary

  • PLN-101095 FORTIFY Phase 1b enrollment is ahead of schedule; interim data are expected in 2027.

  • Integrin-mediated siRNA delivery showed >75% target-gene knockdown at eight weeks in non-human primates, with selective delivery to targeted extrahepatic tissues.

  • Q3 net loss narrowed to $24.4M from $26.3M YoY; 9M net loss fell to $66.8M from $125.8M, mainly reflecting lower spending after bexotegrast discontinuation and restructuring.

Financial highlights

  • Q3 2026 operating expenses were $25.7M vs. $28.3M YoY; R&D was $17.9M vs. $17.9M and G&A was $7.8M vs. $10.3M.

  • 9M 2026 operating expenses were $71.4M vs. $132.8M YoY; R&D was $48.2M vs. $93.6M and G&A was $23.1M vs. $39.2M.

  • Q3 net loss per share was $0.39 vs. $0.43 YoY; 9M loss per share was $1.08 vs. $2.05.

  • Q3 interest and other income was $1.4M vs. $2.8M YoY; interest expense was zero vs. $0.8M in Q3 2025.

Outlook and guidance

  • Cash, cash equivalents and short-term investments of $142.6M at September 30, 2026, were expected to fund operations to mid-2028.

  • R&D expense is expected to remain relatively consistent near term, increasing with PLN-101095 Phase 1b progress; G&A expense is expected to remain relatively consistent.

  • FORTIFY is enrolling up to 102 patients across NSCLC, clear cell renal cell carcinoma and high-TMB cohorts; interim data are expected in 2027.

  • The auction and disposal of held-for-sale assets are expected to conclude by December 31, 2026.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Pliant Therapeutics earnings date

Logotype for Pliant Therapeutics Inc
Q4 20262 Mar, 2027
Pliant Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Pliant Therapeutics earnings date

Logotype for Pliant Therapeutics Inc
Q4 20262 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Pliant Therapeutics, Inc. (PTI) is a clinical stage biopharmaceutical company developing DNA-based therapeutics that enable patients to reverse fibrosis and related diseases. The company's lead product candidate, PRTX-100, is a proprietary plasmid DNA therapeutic that has completed Phase 2 testing in nonalcoholic steatohepatitis (NASH). PTI owns the rights to exclusive plasmid-based therapies optimized for solid tumors including breast and pancreatic cancers. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.